Recommended dose is 200 mg every 2 weeks as a subcutaneous injection1
KEVZARA can be used with or without MTX or other conventional DMARDs1*
Reduce the 200 mg dose to 150 mg for the management of neutropenia, thrombocytopenia, or elevated liver enzymes1
Click here for dosing considerations for patient management
*Dosing of MTX and other conventional DMARDs may vary.
KEVZARA is available by prescription only.
Both the KEVZARA packaging and prefilled syringe received the Arthritis Foundation Ease of Use Commendation after independent testing by experts and evaluation by people with arthritis. Products receiving the Commendation make certain aspects of life easier for people with RA.2,3
DMARD=disease-modifying antirheumatic drug.
References: 1. KEVZARA [prescribing information]. Bridgewater, NJ: Sanofi/Regeneron Pharmaceuticals, Inc; 2017. 2. Ease of use products. Arthritis Foundation website. http://www.arthritis.org/living-with-arthritis/tools-resources/ease-of-use. Accessed October 10, 2017. 3. Data on file, Sanofi/Regeneron. Regeneron Sarilumab Evaluation Report of Consumer Product Accessibility for Users with Arthritis. February 2015.